Scynexis Inc., of Jersey City, N.J., reported data demonstrating the antifungal activity of ibrexafungerp as an agent to address vulvovaginal candidiasis (VVC). The data, which were presented at the 2019 American College of Obstetrics and Gynecology meeting in Nashville, Tenn., further support the company's plan to submit a new drug application for VVC in the second half of 2020.